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Abstract. As a result of widespread antimalarial drug resistance, all African countries with endemic malaria have, in
recent years, changed their malaria treatment policy. In Senegal, the health authorities changed from chloroquine (CQ)
to a combination of sulfadoxine–pyrimethamine (SP) plus amodiaquine (AQ) in 2003. Since 2006, the artemisinin com-
bination therapies (ACTs) artemether–lumefantrine (AL) and artesunate plus amodiaquine (AS/AQ) were adopted for
uncomplicated malaria treatment. After several years of CQ withdrawal, the current study wished to determine the level
of CQ resistance at the molecular level in selected sites in Senegal, because the scientific community is interested in
using CQ again. Finger prick blood samples were collected from Plasmodium falciparum-positive children below the
age of 10 years (N = 474) during cross-sectional surveys conducted in two study sites in Senegal with different malaria
transmission levels. One site is in central Senegal, and the other site is in the southern part of the country. All sam-
ples were analyzed for single nucleotide polymorphisms (SNPs) in the P. falciparum CQ resistance transporter gene
(Pfcrt; codons 72–76) using polymerase chain reaction (PCR) sequence-specific oligonucleotide probe (SSOP) enzyme-
linked immunosorbent assay (ELISA) and real-time PCR methods. In total, the 72- to 76-codon region of Pfcrt was
amplified in 449 blood samples (94.7%; 285 and 164 samples from the central and southern sites of Senegal, respectively).
In both study areas, the prevalence of the Pfcrt wild-type single CVMNK haplotype was very high; in central Senegal,
the prevalence was 70.5% in 2009 and 74.8% in 2010, and in southern Senegal, the prevalence was 65.4% in 2010 and
71.0% in 2011. Comparing data with older studies in Senegal, a sharp decline in the mutant type Pfcrt prevalence is
evident: from 65%, 64%, and 59.5% in samples collected from various sites in 2000, 2001, and 2004 to approximately
30% in our study. A similar decrease in mutant type prevalence is noted in other neighboring countries. With the
continued development of increased CQ susceptibility in many African countries, it may be possible to reintroduce CQ
in the near future in a drug combination; it could possibly be given to non-vulnerable groups, but it demands close
monitoring of possible reemergence of CQ resistance development.
INTRODUCTION
Chloroquine (CQ) resistance in Plasmodium falciparum is
well-established in many parts of Africa, including Senegal,1
where resistance to CQ was first reported in Dakar in 1988.2
High rates of CQ treatment failures and an increased risk
of childhood malaria deaths3 prompted Senegalese health
authorities to abandon CQ in 2003. Sulfadoxine–pyrimethamine
(SP) plus amodiaquine (AQ) was then introduced as the first-
line treatment of uncomplicated P. falciparum malaria, despite
the fact that low numbers of SP and AQ treatment failures
were documented in the country when used alone.4–6 SP/AQ
is expected to suppress or at least delay the emergence of
P. falciparum malaria drug resistance, because both drugs
have independent modes of action and unrelated biochemical
targets. In 2006, following the World Health Organization
(WHO) guidelines suggesting the use of artemisinin combina-
tion therapies (ACTs) for uncomplicated malaria treatment,
which were recently re-emphasized in the second edition of
its guidelines published in 2010,7 the combination SP/AQ was
changed toACTs: artemether–lumefantrine (AL)andartesunate
plus AQ (AS/AQ) are first-line treatments (depending on
availability) against uncomplicated malaria in Senegal. This
policy decision was supported by the finding that AS/AQ was
highly effective in Senegal.8 Presumably, as an effect of this
decision, a large reduction of confirmed malaria cases was
noted between 2005 and 2009 among children under 5 years
of age.9 Furthermore, the use of ACT may have contributed
to the 30% reduction in all mortality among children under
5 years of age as observed in Senegal over the same time
period.10 From September of 2007, the use of malaria rapid
diagnostic tests (RDTs) was incorporated by the National
Malaria Control Program (NMCP) into a revised national
policy for management of febrile illness. Since that time,
ACT use has been restricted to confirmed malaria cases to
reduce drug pressure. CQ resistance (CQR) has been linked
to 15 polymorphisms in the P. falciparum CQ resistance trans-
porter gene (Pfcrt) from different parts of the world,11–14 as
well as mutations in the Plasmodium falciparum multidrug
resistance (Pfmdr1) gene.15,16 However, the most important is
a single codon change at position 76 (K76T) found in all
natural CQR isolates to date.17 Furthermore, substitutions in
the wild-type haplotype at codons 72–76 (CVMNK) led to sev-
eral resistant haplotypes, the most common of which are the
CVIET haplotype, which is highly prevalent in southeast Asia
and Africa, and SVMNT, which has been reported in South
America11 and Asia18 but rarely Africa.19 Thus, the CVIET
haplotype or the single nucleotide polymorphism (SNP) at
Pfcrt76T has been shown to be a suitable tool for monitoring
Pfcrt resistance in Africa. As CQ is replaced by AL and AS/
AQ in Senegal and there is the possibility that drugs previ-
ously compromised by resistance can regain efficacy and
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could be used again, it becomes important from an epidemi-
ological point of view to monitor changes in frequency of
CQR markers (CVIET) after several years withdrawal of CQ
for uncomplicated malaria treatment in Senegal.
MATERIALS ANDMETHODS
The samples for this study were collected from children
under 10 years of age during cross-sectional studies conducted
from 2009 to 2011 in one central site consisting of three dis-
tricts (Mbour, Fatick, and Bambey) and one southern site
consisting of three districts (Tambacounda, Velingara, and
Saraya) in Senegal. Study sites are 400 km apart and charac-
terized by different malaria transmission patterns. The central
part has 4 months of rainy season from July to October, with
an entomological inoculation rate (EIR) of 12 infectious bite
per night per person, whereas the southern part has 6 months
of rainy season from June to November, with a mean of
EIR = 264 infected bites during the malaria transmission
season.20 In both areas, the Anopheles gambiae complex is
responsible for malaria transmission. Before blood sample
collection, written informed consent was obtained from the
parent or guardian of each child. The study was approved by
the Ethics Committee of Senegal. During the study, if chil-
dren presented to health huts with symptoms consistent with
mild malaria, including fever, chills, headache, and a positive
RDT, they were offered standard ACT first-line treatment.
Finger prick blood samples were collected from each study
participant and blotted onto Whatman filter paper 3MM.
Samples were stored at room temperature protected with
silica gel desiccant for later P. falciparum DNA isolation.
Thick and thin blood films were also done for microscopical
identification of Plasmodium species.
DNA extraction and genetic analysis. P. falciparum DNA
was extracted from positive finger prick blood spots by
the Chelex-100 method described in the work by Wooden
and others,21 with some modifications described in the work
by Pearce and others.22 Different methods for CQR geno-
typing at codons 72–76 based on polymerase chain reaction
(PCR) were used. Quantitative PCR (Q-PCR) and nested
PCR were followed by a sequence-specific oligonucleotide
probe–enzyme-linked immunosorbent assay (SSOP-ELISA).
For samples from the central study site, the Q-PCR assay was
carried out using double-labeled probes, with a different
fluorophore on each probe representing the three most com-
mon Pfcrt 72–76 alleles (wild-type [CVMNK] and resistance-
associated [CVIET and SVMNT] haplotypes), and previously
described conditions for amplification.23 Amplification was
performed in a Rotor-gene 2000 Real Time cycler machine
in the presence of each of the three double-labeled probes
described previously.23 Control parasite DNA was obtained
directly from MR4 (ATCC, Manassas, VA). Samples were
considered positive for a particular genotype if a cycle thresh-
old (CT) value of 35 cycles or less was obtained in at least
two independent PCR experiments.
For samples from the southern study site, a nested PCR
described in the work by Djimde and others12 was used to
amplify fragments of the Pfcrt gene. The only modification
was that primers TCRD2 in the Pfcrt nested PCRs were
biotinylated at the 5-end by the supplier (www.mwg-biotech
.com).24 The 20-mL Pfcrt outer PCR mixture consisted of
the primers P1/P2 (1 mM/primer), 1.0 + TEMPase Hot Start
Master Mix (3.0 mM MgCl2, 0.4 mM 2¢-deoxynucleoside
5¢-triphosphate [dNTP], and 0.2 units/mL TEMPase Hot
Start DNA Polymerase, Ampliqon III; VWR-Bie, Berntsen,
Denmark), and 1 mL extracted DNA. The reaction mixture
of the nested Pfcrt PCR was identical to the mixture of
the outer PCR, and the primer set TCRD1/TCRD2-biotin
was used. Genomic DNA preparation of laboratory isolates
3D7, Dd2, and 7G8 were included as references for wild-
type CVMNK and mutant types CVIET and SVMNT
haplotypes, respectively. Amplifications were performed in
96-well PCR microplates. The nested PCR products were
confirmed by running the controls by electrophoresis on a
1.5% agarose gel.
SSOP-ELISA. This method has been described in the work
by Alifrangis and others.25 Briefly, biotin-conjugated nested
PCR products were fixed on streptavidin-coated ELISA
plates and incubated overnight at 4°C. After washing three
times in washing buffer (1 + phosphate-buffered saline [PBS]
with 0.05% Tween 20), digoxigenin-labeled oligonucleotide
probes with specificity for the haplotypes of interest (CVMNK,
CVIET, or SVMNT) were added to each plate and incubated
for 1 hour at 53°C. The mixtures were washed with high strin-
gency at 60°C two times for 10 minutes before they were incu-
bated for 1 hour with peroxidase-conjugated antidigoxigenin
antibodies (Roche Diagnostics, Mannheim, Germany) and
visualized by o-phenylene-diamine (OPD; Dako, Glostrup,
Denmark). The SSOP is able to detect both single and mixed
haplotypes with high specificity. For each analyses, parasite
samples were categorized into single or mixed infections. Infec-
tions were considered to be single haplotype when only one
was present at optical density (OD) values above the threshold
of positivity. Conversely, samples were considered to be mixed
if OD values for both haplotypes were above the threshold
of positivity. For statistical analysis purposes and adherence
to Q-PCR data, parasites carrying the CVMNK haplotype
only were classified as wild-type parasite infections, whereas
parasite harboring both CVMNK and CVIET haplotypes
were considered as resistant parasite infections.
Statistical analysis. OD values obtained from the ELISA
reader were entered in a Microsoft Excel sheet, and the
haplotype of each positive sample was determined. Statistical
analyses of data were performed with Epi info 6.04a (http://
www.cdc.gov/epiinfo/Epi6/EI6dnjp.htm). A c2 test was used
to compare differences in proportions of parasites genotypes.
Significance level of statistical tests was set at 0.05 with
two sides.
RESULTS
Overall, 9,549 (6,000 in 2009 and 3,549 in 2010) samples
were collected from the central site of Senegal, and 1,903
(804 in 2010 and 1,099 in 2011) samples were collected
from the southern site. Combining the data, malaria, based
on RDT, was more prevalent in the southern site (12.3%;
234/1,903) compared with the central site (3.1%; 298/9,549;
P < 0.001). In the same sites from year to year, malaria
prevalence was not different (Table 1).
Overall, 532 samples were P. falciparum RDT-positive at
both sites. Of these samples, 474 parasites isolates were con-
firmed by microscopy to be P. falciparum only, and 58 iso-
lates were identified as mixed species (P. falciparum plus
P. malariae). The 474 parasite isolates were used for the
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PCR analysis, whereas the mixed species infections were
excluded from additional analysis.
PCR efficacy. Of these isolates, the sequence of 94.7%
(449/474) of samples was successfully determined at codons
72–76 of the Pfcrt gene using PCR-SSOP-ELISA or Q-PCR
as shown in Table 2.
Prevalence of Pfcrt haplotypes in central and southern
study sites of Senegal. Results based on the two methodolo-
gies were comparable (data not shown), and they revealed
that the CVMNK (wild type) haplotype and the CVIET
mutant CQR type were present, whereas the SVMNT haplo-
type was not found in our samples.
Overall, our results show a high prevalence of wild-type
CVMNK haplotype in both years and by site. In the central
study site, the prevalence of samples containing parasites
harboring the CVMNK haplotype was 80% (117/146) in 2009
and 83% (115/139) in 2010, with no significant difference
between the years (P = 0.57) (Figure 1). In the southern
study site area, similar results were found; the prevalence of
CVMNK was 80% (65/81) in 2010, whereas the prevalence
of CVMNK was 82% (68/83) in 2011 (P = 0.78) (Figure 1).
Conversely, the prevalence of the CVIET haplotype, includ-
ing mixed haplotype infections, was 29% (43/146) in 2009 and
25% (35/139) in 2010, with no significant difference between
the years (P = 0.49). In the southern study site, similar results
were found; the prevalence of CVIET was 35% (28/81) in
2010, whereas it decreased to 29% (24/83) in 2011 (P = 0.43).
DISCUSSION
Drug resistance is a recurrent theme in the history of infec-
tious disease control. In the case of malaria, resistance to
previously effective drugs, such as CQ and SP, is widespread
in sub-Saharan Africa.24 After resistance was identified, the
WHO recommended the use of ACTs, which have now
been adopted and implemented in most African countries.7
The Senegalese health authorities, through the NMCP,
adopted AS/AQ and AL for uncomplicated malaria treat-
ment in 2006 (depending on availability). With concerns
about emerging ACT resistance in Asia,26,27 alternative
approaches for malaria control are needed, new drugs need
to be developed, and lastly, the possibility of reintroducing
abandoned drugs needs to be explored. For instance, the pos-
sibility that drugs, such as CQ, previously compromised by
resistance can regain efficacy has been observed in Malawi,
and it should be investigated. In Malawi, the withdrawal of
CQ from the health system was accompanied by a reduction
in the prevalence of the molecular marker of CQR (the Pfcrt
T76 allele) from 85% to 13% between 1992 and 2000.28
Recently, Kenya and Tanzania have also reported a decline
in CQR after replacement of CQ by SP; however, this decline
occurred at a somewhat slower rate than in Malawi.29,30
In all, this finding supports the notion that CQR parasites
are less fit than wild-type parasites in the absence of CQ
drug pressure.31,32 This study investigated the molecular level
of CQ resistance by examining the prevalence of Pfcrt. The
P. falciparum-positive samples were collected in sites in cen-
tral and southern Senegal several years after official CQ with-
drawal as first-line treatment of uncomplicated malaria. Our
results showed that the prevalence of single Pfcrt CVMNK
wild-type haplotype was high (above 70% and 60% in central
and southern study areas, respectively). By comparing our
data with previous studies on SNPs in the Pfcrt gene done on
samples from Senegal, it seems that the prevalence of the
mutant CVIET (76T) haplotype has decreased dramatically
(from a prevalence of 76T, including mixed 76K/76T infec-
tions, of 65%, 64%, and 59.5% on samples collected from
various sites in Senegal in 2000, 2001, and 2004, respec-
tively,33–36 to approximately 30% in our study) (Figure 1).
Table 2
Prevalence of Pfcrt haplotype (CVMNK, CVIET, and mixed) in our study area
Years
Central site Southern site
2009 2010 2010 2011
Number of samples analyzed 155 143 81 153
Total positive by PCR 146 139 81 83
CVMNK single infections 103 (70.5%) 104 (74.8%) 53 (65.4%) 59 (71.0%)
CVIET single infections 29 (19.8%) 24 (17.2%) 16 (19.7%) 15 (18.0%)
Mixed CVMNK/CVIET infections 14 (9.5%) 11 (7.9%) 12 (14.8%) 9 (10.8%)
Table 1
Baseline characteristics for malaria prevalence in the study sites
Years
Central site Southern site
2009 2010 P 2010 2011 P
No bloodspot collected 6,000 3,549 804 1,099
Total positive for
P. falciparum by RDT
155 143 81 153
Malaria prevalence 2.6% 4.0% 0.65 10.1% 14.0% 0.39
Figure 1. Prevalence of haplotypes in codons 72–76 of the Pfcrt
gene in the study areas. Central site includes Mbour, Fatick, and
Bambey. Southern site includes Tambacounda, Velingara, and
Saraya. Mixed CVIET and CVMNK are included in both sites.
CVIET = mutant type; CVMNK = wild type.
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Compared with these older studies, it is plausible that a gen-
eral trend to a dramatic decrease in Pfcrt mutant types has
happened throughout the country. The low decrease of CQR
haplotype observed in previous studies could be because of
(1) ongoing CQ pressure despite national policy changes or
(2) the fact that the samples were collected in a suburb of
Dakar (Pikine), which is a malaria hypoendemic area. The
low level of estimated CQ use in Senegal is associated with a
declining prevalence of CQR. Thus, in all, the data suggest
that the increase in prevalence of Pfcrt wild types is occur-
ring country-wide, although with the precaution that the
samples were collected at different sites and based on other
sampling designs compared with the present study. High
prevalence of the Pfcrt 76K wild type was observed in neigh-
boring Guinea Bissau as early as 2001 and 2004, where the
prevalence of Pfcrt K76 wild type was found at 82%, proba-
bly because of the fact that CQ has been used at high doses
(76 mg/kg). The work by Ursing and others37 showed that
high doses of CQ were at least two times more efficacious
when treating P. falciparum with Pfcrt 76T. In neighboring
Mali, studies conducted from 1996 to 2004 showed a slow
decrease of Pfcrt 76T caused by a decrease in but not elimi-
nation of CQ use between 2000 and 2006.38
The increase in prevalence of the Pfcrt wild type from
2004 on shown by comparing the limited number of studies
in Senegal with the current study is most likely caused by
synergic factors of withdrawal of CQ since 2003 and possibly,
the introduction of ACT (AL or AS/AQ) for treatment in
2006 as well, because significant selection of the Pfcrt K76
allele after AL treatment has been shown.39 In addition, in
2007, RDTs were introduced to improve malaria diagnosis
before malaria treatment, which has reduced drug pressure on
P. falciparum parasites, because only confirmed P. falciparum
cases optimally will receive ACT treatment. Thus, our find-
ings, in concert with similar observations in countries such
as Malawi,28 Kenya,29 and Tanzania,30 suggest that CQ might
once again be used combined with other antimalarials for
malaria prevention or treatment in the near future. Alterna-
tive use of CQ combined with other antimalarial drugs for
malaria prevention in, for example, non-vulnerable groups
may be a realistic option. Intermittent preventive treatment
of malaria in children (IPTc) is now a new strategy for
reducing malaria morbidity among children. IPTc involves
administration of antimalarial drugs at defined time intervals
to individuals, regardless of whether they are known to be
infected with malaria, to prevent morbidity and mortality from
the infection.40 IPTc has been shown to be effective in reduc-
ing malaria burden by several studies.41,42 Indeed, to ensure a
maximum protective effect, the IPTc strategy should pref-
erably combine two long half-life drugs.43 The combination of
SP/AQ is currently the most optimal regimen. However, other
than this combination, few options are available for IPTc.
In this context, the combination of CQ and piperaquine or
SP should be investigated as an option for IPTc. One major
demand for testing such a strategy would be the close and
continuous monitoring of CQ resistance, where the prevalence
of Pfcrt would most likely provide a sensible guideline.
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